Werewolf Therapeutics, Inc.
HOWL
$0.63
-$0.03-4.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -43.09% | 1,016.55% | |||
| Gross Profit | 43.09% | -1,016.55% | |||
| SG&A Expenses | -33.46% | -6.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -40.11% | -10.35% | |||
| Operating Income | 40.11% | 10.35% | |||
| Income Before Tax | 48.80% | 8.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 48.80% | 8.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 48.80% | 8.96% | |||
| EBIT | 40.11% | 10.35% | |||
| EBITDA | 41.15% | 10.57% | |||
| EPS Basic | 51.57% | 10.61% | |||
| Normalized Basic EPS | 51.57% | 10.60% | |||
| EPS Diluted | 45.39% | 10.00% | |||
| Normalized Diluted EPS | 52.37% | 10.60% | |||
| Average Basic Shares Outstanding | 5.72% | 1.83% | |||
| Average Diluted Shares Outstanding | 7.45% | 1.83% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||